TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22185349

Group type: EXPERIMENTAL
Intervention: Non-tactile loving-kindness meditation (LKM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tactile loving-kindness meditation (LKM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline (neutral reading)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Post-Intervention Rest (reading)
Number of subjects: 10
Study: 18470565

Group type: EXPERIMENTAL
Intervention: 0.2 percent glyceryl trinitrate suppository (n = 21)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 34
Study: 16482475

Group type: EXPERIMENTAL
Intervention: Squat only (S)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of WBV and squat (S+V)
Number of subjects: 28

Group type: COMPARATOR
Intervention: WBV only (V)
Number of subjects: 28
Study: 12414081

Group type: EXPERIMENTAL
Intervention: Cognitive assessments in English-speaking countries and translated tests in other languages
Number of subjects: 301

Group type: COMPARATOR
Intervention: Cognitive assessments in English-speaking countries
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Cognitive assessments in translated languages
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Cognitive assessments across different countries
Number of subjects: 301
Study: 10910008

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9048788

Group type: EXPERIMENTAL
Intervention: CDP571 (5 mg/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (human albumin)
Number of subjects: 31
Study: 8103616

Group type: EXPERIMENTAL
Intervention: 300 mg/daily ranitidine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 40 mg/daily famotidine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 300 mg/daily nizatidine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 40 mg/daily omeprazole
Number of subjects: 54
Study: 3092894

Group type: EXPERIMENTAL
Intervention: PTBD + hyperalimentation
Number of subjects: 64

Group type: COMPARATOR
Intervention: PTBD alone
Number of subjects: 64
Study: 29521797

Group type: EXPERIMENTAL
Intervention: Platelets stored at 4°C for up to 5, 10, or 15 days
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Platelets stored at 22°C for up to 5 days
Number of subjects: 1500
Study: 28490555

Group type: EXPERIMENTAL
Intervention: Telehealthcare
Number of subjects: 574

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 574
Study: 26151620

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (32 IU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23430442

Group type: EXPERIMENTAL
Intervention: Sox2 overexpression in HCC cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High Sox2 expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sox2 expression
Number of subjects: 0
Study: 21495216

Group type: EXPERIMENTAL
Intervention: Lymph node sampling and blind biopsies (group A)
Number of subjects: 448

Group type: COMPARATOR
Intervention: No lymph node sampling (group B)
Number of subjects: 448

Group type: COMPARATOR
Intervention: No blind biopsies (group C)
Number of subjects: 448
Study: 18426137

Group type: EXPERIMENTAL
Intervention: Azelastine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17249435

Group type: EXPERIMENTAL
Intervention: 35% H2O2 + acetone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: H2O2 + ethanol
Number of subjects: 40

Group type: COMPARATOR
Intervention: acetone
Number of subjects: 40

Group type: COMPARATOR
Intervention: ethanol
Number of subjects: 40
Study: 14994771

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin (oral)
Number of subjects: 20
Study: 11129366

Group type: EXPERIMENTAL
Intervention: Structured writing about stressful events
Number of subjects: 105
Study: 9488244

Group type: EXPERIMENTAL
Intervention: CS-866 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CS-866 20 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CS-866 80 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CS-866 (all doses above 5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CS-866 (2.5 to 10 mg and 5 to 20 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CS-866
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8452167

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily
Number of subjects: 474

Group type: COMPARATOR
Intervention: Ceftazidime 0.5-2 g three times a day or 1-2 g twice a day
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Uncontrolled trial with Fleroxacin
Number of subjects: 474
Study: 3085738

Group type: EXPERIMENTAL
Intervention: Sodium Valproate (SV) 800 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31834177

Group type: EXPERIMENTAL
Intervention: 12-week combined training intervention (resistance and aerobic exercise)
Number of subjects: 0
Study: 30158160

Group type: EXPERIMENTAL
Intervention: Unilateral focused ultrasound thalamotomy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 27
Study: 27508937

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT) in addition to care as usual (CAU), n = 65
Number of subjects: 131

Group type: COMPARATOR
Intervention: Care as usual (CAU), n = 66
Number of subjects: 131
Study: 24958780

Group type: EXPERIMENTAL
Intervention: Norwood procedure
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Blalock-Taussig shunt
Number of subjects: 498
Study: 22632734

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB‐UVB) exposure three times per week
Number of subjects: 73

Group type: COMPARATOR
Intervention: Oral vitamin D(3) supplementation 1600 IU (40 μg) per day
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study: 20420759

Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM) (50 g fat)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate meal (HCM) (5 g fat)
Number of subjects: 30
Study: 18217177

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 208
Study: 11115412

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily for 4 weeks)
Number of subjects: 12
Study: 9117878

Group type: EXPERIMENTAL
Intervention: RV16 treatment (0.5-2.9 x 10(4) TCID50)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: RV16 treatment
Number of subjects: 27
Study: 7709688

Group type: EXPERIMENTAL
Intervention: GnRH-Analogues
Number of subjects: 0
Study: 2954222

Group type: EXPERIMENTAL
Intervention: Balans chair
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional office chair
Number of subjects: 20
Study: 31846974

Group type: EXPERIMENTAL
Intervention: High c-Met expression in primary HCC cases
Number of subjects: 319

Group type: COMPARATOR
Intervention: Low c-Met expression in primary HCC cases
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: High c-Met expression in 40 cases
Number of subjects: 319
Study: 30376095

Group type: EXPERIMENTAL
Intervention: bOPV followed by IPV at 14 weeks
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 1 IPV at 8 weeks followed by 2 doses of bOPV
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Second IPV dose at 16 weeks
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Sequential IPV-bOPV
Number of subjects: 260

Group type: COMPARATOR
Intervention: Mixed bOPV-IPV schedule
Number of subjects: 260
Study: 27935537

Group type: EXPERIMENTAL
Intervention: Biocompatible PD solution
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Peritoneal ultrafiltration (UF)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Dialysate glucose exposure
Number of subjects: 161
Study: 25610918

Group type: EXPERIMENTAL
Intervention: Mouthwash containing 2% green tea
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 110
Study: 22197120

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT; 3-minute intervals at 40% and 80% VO(2peak))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT; sustained 60% VO for 30 min/day, 3 days/week for 12 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: General Healthcare (GHC)
Number of subjects: 45
Study: 21262565

Group type: EXPERIMENTAL
Intervention: Aripiprazole (up to 15 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 18234392

Group type: EXPERIMENTAL
Intervention: Narrowband UVB
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UVA1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (opaque tape)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (sunscreen)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (unprotected)
Number of subjects: 20
Study: 17165277

Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast + Desloratadine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levocetirizine, 5 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast, 5 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast + Levocetirizine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast + Antihistamine (Desloratadine or Levocetirizine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast + Antihistamine
Number of subjects: 40
Study: 14556770

Group type: EXPERIMENTAL
Intervention: Lymphatic reflexology technique
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Relaxing reflexology technique
Number of subjects: 55

Group type: COMPARATOR
Intervention: Period of rest
Number of subjects: 55
Study: 10892625

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) therapy, 6 hours/day for 6 weeks, targeting supraspinatus and posterior deltoid muscles.
Number of subjects: 0
Study: 8896952

Group type: EXPERIMENTAL
Intervention: 20% sodium dodecyl sulfate (SDS)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 10% hydrochloric acid (HCl)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: undiluted cocotrimethyl ammonium chloride (coco TAC)
Number of subjects: 58
Study: 1356519

Group type: EXPERIMENTAL
Intervention: Ebrotidine (800 mg)
Number of subjects: 20
Study: 30945430

Group type: EXPERIMENTAL
Intervention: Moisturizer containing 5% panthenol, madecassoside, and copper-zinc-manganese (experimental cream)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.02% Triamcinolone acetonide cream (TA cream)
Number of subjects: 20
Study: 29241431

Group type: EXPERIMENTAL
Intervention: Peer Navigator Program (PNP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 110
Study: 26859559

Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF) - 1 sachet/day for 14 days
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) - 2 sachets/day for 14 days
Number of subjects: 2213

Group type: COMPARATOR
Intervention: Control - no supplement
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: RUTF vs Control
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: MNP vs Control
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: RUTF vs MNP
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: RUTF
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: MNP
Number of subjects: 2213

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2213
Study: 24863949

Group type: EXPERIMENTAL
Intervention: Vildagliptin-metformin combination regimen
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard-of-care metformin monotherapy
Number of subjects: 2000
Study: 22175269

Group type: EXPERIMENTAL
Intervention: Prescription review sent to physician
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prescription review sent to physician and current comprehensive medication record sent to the patient
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 18783424

Group type: EXPERIMENTAL
Intervention: Standard U‐shaped bar (Dolder bar) - Group A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attachment bar - Group B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both bar designs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attachment bar
Number of subjects: 0
Study: 18418965

Group type: COMPARATOR
Intervention: Western medicine (WM) group treated with aspirin, Clopidogrel, statins
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional Chinese medicine (TCM) group treated with Dahuang Zhechong Pill, Tianma Duzhong Capsule, and self‐formulated decoctions
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Integrative medicine (IM) group treated with both TCM and WM
Number of subjects: 70
Study: 16178131

Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) rinse (Crest Pro‐Health Rinse)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Essential oils (EO) rinse (Cool Mint Listerine)
Number of subjects: 78
Study: 14606705

Group type: EXPERIMENTAL
Intervention: 0.8 mg Talpha1 (low dose group; n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.6 mg Talpha1 (high dose group; n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Talpha1 therapy
Number of subjects: 16
Study: 10772202

Group type: EXPERIMENTAL
Intervention: Neonatal hemolytic illness
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Total bilirubin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bilirubin/albumin ratio
Number of subjects: 45
Study: 8894384

Group type: EXPERIMENTAL
Intervention: Decision support system for oral hypoglycaemic therapy
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group (normal procedures)
Number of subjects: 218
Study: 1893092

Group type: EXPERIMENTAL
Intervention: Attended tones (specific pitches and ear)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ignored tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feature-conjunction operations
Number of subjects: 0
Study: 6466184

Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine hydrochloride eyedrops
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 30896452

Group type: EXPERIMENTAL
Intervention: Sympathectomy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 79
Study: 30021449

Group type: EXPERIMENTAL
Intervention: Immediate treatment (IG)
Number of subjects: 4685

Group type: COMPARATOR
Intervention: Delayed treatment (DG)
Number of subjects: 4685

Group type: EXPERIMENTAL
Intervention: Cost of early treatment
Number of subjects: 4685
Study: 27287084

Group type: EXPERIMENTAL
Intervention: LNG/EE extended regimen (84 days of LNG 150 μg/EE 30 μg with 7 days of EE 10 μg)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: LNG/EE 21/7 (21 days of LNG 100 μg/EE 20 μg with 7 days of placebo)
Number of subjects: 829

Group type: COMPARATOR
Intervention: Reference group (not using hormonal contraceptives)
Number of subjects: 829
Study: 25175787

Group type: EXPERIMENTAL
Intervention: Mobile phone-based home exercise training program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (free walk)
Number of subjects: 26
Study: 21954131

Group type: EXPERIMENTAL
Intervention: ESCAPE‐knee pain program
Number of subjects: 418

Group type: COMPARATOR
Intervention: Usual care (pragmatic control)
Number of subjects: 418
Study: 19228250

Group type: EXPERIMENTAL
Intervention: Peer-mentored (PM) fitness program
Number of subjects: 131

Group type: COMPARATOR
Intervention: Student-mentored (SM) fitness program
Number of subjects: 131
Study: 18341239

Group type: EXPERIMENTAL
Intervention: Modern clinical testing protocol for controlled clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Categories of assessment for esthetic evaluation, functional assessment, biological responses to restorative materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis of results
Number of subjects: 0
Study: 14973528

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5-2.5 mg daily for 4 months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 84
Study: 11245843

Group type: EXPERIMENTAL
Intervention: Target merging (merging pairs of items, e.g., connecting item locations with a line segment or drawing the convex hull)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9840855

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance with 20 mL 0.5% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nerve stimulator (NS) guidance with 20 mL 0.5% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nerve stimulator (NS) guidance with 30 mL 0.5% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nerve stimulator (NS) guidance
Number of subjects: 60
Study: 8089391

Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PAL)
Number of subjects: 1713

Group type: EXPERIMENTAL
Intervention: Practitioners with fitting skills
Number of subjects: 1713

Group type: COMPARATOR
Intervention: Practitioners without fitting skills
Number of subjects: 1713
Study: 2510959

Group type: EXPERIMENTAL
Intervention: Urokinase therapy (two weeks administration)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Urokinase therapy (consecutive administration)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Antiplatelet drugs (control)
Number of subjects: 57
Study: 52896

Group type: EXPERIMENTAL
Intervention: Ethyloestrenol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methenolone acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norethandrolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylandrostenediol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxymetholone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methandienone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stanozolol
Number of subjects: 0
Study: 30753776

Group type: EXPERIMENTAL
Intervention: Intervention community (educational intervention to prevent childhood obesity)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control community (no intervention)
Number of subjects: 214
Study: 28822956

Group type: EXPERIMENTAL
Intervention: Internet-based intervention (mobile-oriented site)
Number of subjects: 17
Study: 26353947

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Non-metformin antidiabetic medications
Number of subjects: 540

Group type: COMPARATOR
Intervention: No antidiabetic medication
Number of subjects: 540
Study: 22893251

Group type: EXPERIMENTAL
Intervention: Haloperidol treatment
Number of subjects: 88
Study: 20730613

Group type: EXPERIMENTAL
Intervention: CT fluoroscopy-guided NAB (Group I, n = 72)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional CT-guided NAB (Group II, n = 70)
Number of subjects: 142
Study: 18946177

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus with gastroparesis
Number of subjects: 55

Group type: COMPARATOR
Intervention: Patients without gastroparesis or healthy controls
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus with autonomic neuropathy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus without autonomic neuropathy
Number of subjects: 55
Study: 16996462

Group type: EXPERIMENTAL
Intervention: Interactive computer-based method (CD-ROM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional paper-based method
Number of subjects: 39
Study: 12956916

Group type: EXPERIMENTAL
Intervention: Blood cultures taken within two minutes after tonsillectomy (Group 1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Blood cultures taken 15 minutes after tonsillectomy (Group 2)
Number of subjects: 64
Study: 10811692

Group type: COMPARATOR
Intervention: Dysport 1500 Units
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dysport (500, 1000, or 1500 Units)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dysport (1000 or 1500 Units)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dysport 500 Units
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dysport 1000 Units
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: COMPARATOR
Intervention: Dysport
Number of subjects: 74
Study: 8880292

Group type: EXPERIMENTAL
Intervention: Holy basil leaves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo leaves
Number of subjects: 0
Study: 1995769

Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment (ICT, n = 44)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Regular treatment (RT, n = 53)
Number of subjects: 97
Study: 6402199

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 15 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29325486

Group type: EXPERIMENTAL
Intervention: Intensive client-centred occupational therapy (ICC-OT) - maximum 22 sessions
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual practice - maximum 3 sessions of occupational therapy
Number of subjects: 119
Study: 31159805

Group type: EXPERIMENTAL
Intervention: Structured information delivery, personalised written physical activity prescription (number of steps per day), pedometer, and pedometer logbook.
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Structured information delivery, personalised written physical activity prescription, pedometer, and pedometer logbook.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Verbal advice of physical exercise (Control group).
Number of subjects: 140
Study: 28155057

Group type: EXPERIMENTAL
Intervention: Omentectomy
Number of subjects: 49

Group type: COMPARATOR
Intervention: No omentectomy (Control)
Number of subjects: 49
Study: 26156108

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program for protocol-directed weaning
Number of subjects: 884
Study: 23439346

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low-intensity stretching
Number of subjects: 39

Group type: COMPARATOR
Intervention: Moderate-intensity or high-intensity stretching
Number of subjects: 39
Study: 21971664

Group type: EXPERIMENTAL
Intervention: Glutamine (GLN) 15g/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Milk protein 15g/day (Control)
Number of subjects: 20